Entity

Time filter

Source Type

London, United Kingdom

ViiV Healthcare is a pharmaceutical company specialising in the development of therapies for HIV that was created as a joint venture by Pfizer and GlaxoSmithKline in November 2009 with both companies transferring their HIV assets to the new company. In 2012 Shionogi joined the company. 76.5% of the company is now owned by GlaxoSmithKline, 13.5% by Pfizer and 10% by Shionogi. This ownership structure may change depending upon the achievement of certain milestones.ViiV Healthcare's products have a market share of approximately 19 percent of the global HIV market, which makes it the second largest health care company, following after Gilead Sciences, that is working on the treatment of HIV.ViiV Healthcare's headquarters are in Brentford in the United Kingdom and it has sites in a number of other countries including; the United States, Australia, Belgium, Canada, France, Germany, Italy, Japan, Mexico, the Netherlands, Portugal, Puerto Rico, Russia, Spain and Switzerland. Wikipedia.


Patent
Shionogi & Co. and ViiV Healthcare | Date: 2014-02-21

The present invention features compounds that are HIV integrase inhibitors and therefore are useful in the inhibition of HIV replication, the prevention and/or treatment of infection by HIV, and in the treatment of AIDS and/or ARC.


Patent
ViiV Healthcare and Shionogi & Co. | Date: 2014-03-14

The present invention is to provide a novel compound (I) shown below, having the anti-virus activity; particularly the HIV integrase inhibitory activity, and a drug containing the same, particularly an anti-HIV drug, as well as a process and an intermediate thereof. (wherein


Patent
Shionogi & Co. and ViiV Healthcare | Date: 2015-04-30

The present invention is to provide a novel compound (I) shown below, having the anti-virus activity; particularly the HIV integraso inhibitory activity, and a drug containing the same, particularly an anti-HIV drug, as well as a process and an intermediate thereof. (wherein


The present invention relates to processes for the preparation of the compound VIIa:


Patent
Shionogi & Co. and ViiV Healthcare | Date: 2015-08-05

The present invention features compounds that are prodrugs of HIV integrase inhibitors and therefore are useful in the delivery of compounds for the inhibition of HIV replication, the prevention and/or treatment of infection by HIV, and in the treatment of AIDS and/or ARC.

Discover hidden collaborations